RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Madrigal Pharmaceuticals P/E 2024

Madrigal Pharmaceuticals P/E

-8.07

Madrigal Pharmaceuticals Dividend yield

Ticker

MDGL

ISIN

US5588681057

WKN

A2APCZ

As of May 19, 2024, Madrigal Pharmaceuticals's P/E ratio was -8.07, a -40.04% change from the -13.46 P/E ratio recorded in the previous year.

The Madrigal Pharmaceuticals P/E history

Madrigal Pharmaceuticals Aktienanalyse

What does Madrigal Pharmaceuticals do?

Madrigal Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of top-quality therapy products for various metabolic disorders. The company is headquartered in Conshohocken, Pennsylvania and was founded in 2011. The history of Madrigal Pharmaceuticals Inc began with the collaboration of Fred Middleton and Paul Friedman. Both are experienced drug developers and have already achieved some successes in the industry. They discovered the promising active ingredient resveratrol for the treatment of obesity and other metabolic disorders in mice. The idea of applying this concept to humans led to the founding of Madrigal Pharmaceuticals Inc. The business model of Madrigal Pharmaceuticals Inc consists of developing high-quality peptide and lipid-based drugs. The company specifically focuses on the treatment of metabolic disorders such as non-alcoholic fatty liver disease (NAFLD), lipid metabolism disorders, and NASH (non-alcoholic steatohepatitis). The goal is to develop innovative therapy products that bring about significant improvements in patients. Madrigal Pharmaceuticals Inc has several divisions in research and development. One of the most important specialties is the discovery of ACTOS resistance. ACTOS is a drug used to treat diabetic metabolic disorders. However, Madrigal Pharmaceuticals Inc has recognized that ACTOS does not work in some patients, and that this patient group is at higher risk of obesity, NAFLD, and NASH. Therefore, the company is developing therapeutics that target this patient group and are more effective than ACTOS. Another specialty of Madrigal Pharmaceuticals is the Myocardial Peptide Modulator (MMP). This active ingredient is a potential approach to treating metabolic disorders and heart failure. Another important division of Madrigal Pharmaceuticals Inc is the development of drugs targeting PCSK9 inhibition. PCSK9 is a protein that contributes to increased cholesterol levels. The goal is to improve understanding of the mechanism of action of PCSK9 and its various mechanisms in order to develop effective therapy products. The company has already developed several products that are in the clinical phase and are highly effective. One of the most remarkable products is MGL-3196. This product is a farnesoid X receptor agonist that has proven to be promising in the treatment of NASH and lipid metabolism disorders. Madrigal Pharmaceuticals Inc has also formed partnerships with other companies to strengthen collaboration in the research and development of products. One important partnership is with Shionogi, a Japanese pharmaceutical company. This collaboration has helped develop an innovative therapy product for the treatment of obesity that uses a targeted gene silencer. Overall, Madrigal Pharmaceuticals Inc has established itself as a company that develops innovative products for the treatment of metabolic disorders. The company strives to create the possibility for patients to receive effective therapy that is able to improve the mechanism of action of metabolic disorders. Madrigal Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Madrigal Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Madrigal Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Madrigal Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Madrigal Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Madrigal Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Madrigal Pharmaceuticals Stock

What is the price-to-earnings ratio of Madrigal Pharmaceuticals?

The price-earnings ratio of Madrigal Pharmaceuticals is currently -8.07.

How has the price-earnings ratio of Madrigal Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Madrigal Pharmaceuticals has increased by -40.04% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Madrigal Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Madrigal Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Madrigal Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Madrigal Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Madrigal Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Madrigal Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Madrigal Pharmaceuticals?

Some factors that influence the price-earnings ratio of Madrigal Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Madrigal Pharmaceuticals pay?

Over the past 12 months, Madrigal Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Madrigal Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Madrigal Pharmaceuticals?

The current dividend yield of Madrigal Pharmaceuticals is .

When does Madrigal Pharmaceuticals pay dividends?

Madrigal Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Madrigal Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Madrigal Pharmaceuticals located?

Madrigal Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Madrigal Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Madrigal Pharmaceuticals from 5/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/19/2024.

When did Madrigal Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/19/2024.

What was the dividend of Madrigal Pharmaceuticals in the year 2023?

In the year 2023, Madrigal Pharmaceuticals distributed 0 USD as dividends.

In which currency does Madrigal Pharmaceuticals pay out the dividend?

The dividends of Madrigal Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Madrigal Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Madrigal Pharmaceuticals

Our stock analysis for Madrigal Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Madrigal Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.